,The Drug Abuse Warning Network (DAWN) is a nationally representative public health surveillance system that has monitored drug related emergency department (ED) visits to hospitals since the early 1970s. First administered by the Drug Enforcement Administration (DEA) and the National Institute on Drug Abuse (NIDA), the responsibility for DAWN now rests with the Substance Abuse and Mental Health Services Administration's (SAMHSA) Center for Behavioral Health Statistics and Quality (CBHSQ). Over the years, the exact survey methodology has been adjusted to improve the quality, reliability, and generalizability of the information produced by DAWN. The current approach was first fully implemented in the 2004 data collection year. DAWN relies on a longitudinal probability sample of hospitals located throughout the United States. To be eligible for selection into the DAWN sample, a hospital must be a non-Federal, short-stay, general surgical and medical hospital located in the United States, with at least one 24-hour ED. DAWN cases are identified by the systematic review of ED medical records in participating hospitals. The unit of analysis is any ED visit involving recent drug use. DAWN captures both ED visits that are directly caused by drugs and those in which drugs are a contributing factor but not the direct cause of the ED visit. The reason a patient used a drug is not part of the criteria for considering a visit to be drug-related. Therefore, all types of drug-related events are included: drug misuse or abuse, accidental drug ingestion, drug-related suicide attempts, malicious drug poisonings, and adverse reactions. DAWN does not report medications that are unrelated to the visit. The DAWN public-use dataset provides information for all types of drugs, including illegal drugs, prescription drugs, over-the-counter medications, dietary supplements, anesthetic gases, substances that have psychoactive effects when inhaled, alcohol when used in combination with other drugs (all ages), and alcohol alone (only for patients aged 20 or younger). Public-use dataset variables describe and categorize up to 22 drugs contributing to the ED visit, including toxicology confirmation and route of administration. Administrative variables specify the type of case, case disposition, categorized episode time of day, and quarter of year. Metropolitan area is included for represented metropolitan areas. Created variables include the number of unique drugs reported and case-level indicators for alcohol, non-alcohol illicit substances, any pharmaceutical, non-medical use of pharmaceuticals, and all misuse and abuse of drugs. Demographic items include age category, sex, and race/ethnicity. Complex sample design and weighting variables are included to calculate various estimates of drug-related ED visits for the Nation as a whole, as well as for specific metropolitan areas, from the ED visits classified as DAWN cases in the selected hospitals.This study has 1 Data Set.,

,The Drug Abuse Warning Network (DAWN) survey is designed to capture data on emergency department (ED) episodes that are induced by or related to the use of an illicit, prescription, or over-the-counter drug. For purposes of this collection, a drug "episode" is an ED visit that was induced by or related to the use of an illegal drug or the nonmedical use of a legal drug for patients aged six years and older. A drug "mention" refers to a substance that was mentioned during a drug-related ED episode. Because up to four drugs can be reported for each drug abuse episode, there are more mentions than episodes in the data. Individual persons may also be included more than once in the data. Within each facility participating in DAWN, a designated reporter, usually a member of the emergency department or medical records staff, was responsible for identifying drug-related episodes and recording and submitting data on each case. An episode report was submitted for each patient visiting a DAWN emergency department whose presenting problem(s) was/were related to their own drug use. DAWN produces estimates of drug-related emergency department visits for 50 specific drugs, drug categories, or combinations of drugs, including the following: acetaminophen, alcohol in combination with other drugs, alprazolam, amitriptyline, amphetamines, aspirin, cocaine, codeine, diazepam, diphenhydramine, fluoxetine, heroin/morphine, inhalants/solvents/aerosols, LSD, lorazepam, marijuana/hashish, methadone, methamphetamine, and PCP/PCP in combination with other drugs. The use of alcohol alone is not reported. The route of administration and form of drug used (e.g., powder, tablet, liquid) are included for each drug. Data collected for DAWN also include drug use motive and total drug mentions in the episode, as well as race, age, patient disposition, reason for ED visit, and day of the week, quarter, and year of episode.This study has 1 Data Set.,

This publication describes the methodologies used by the Drug Abuse Warning Network (DAWN), to collect, prepare, and analyze information on drug-related emergency department (ED) visits in the United States. The methods described here were initiated in 2004 and are current as of 2011.

This Drug Abuse Warning Network (DAWN) short report summarizes key findings about drug-related emergency department visits between 2004 and 2010. The report includes data for illicit drugs, alcohol, and prescription and over-the counter medications. For medications, the report looks at misuse and abuse, adverse reactions, and accidental ingestion of drugs by children.

Drug Abuse Warning Network (DAWN) Non-Fatal Overdoses Short Report presents: (1) national estimates and characteristics of non-fatal overdose ED visits, (2) the identification of top substances involved in these visits and (3) the prevalence of polysubstance related non-fatal overdose ED visits. Additional report resources are also available in theNon-Fatal Overdoses Short Report - Companion Document.

This Drug Abuse Warning Network (DAWN) spotlight is about emergency department visits involving nonmedical use of phamaceuticals by gender among older adolescents age 12 to 17 from year 2010.

,Nowelizacja ustawy o przeciwdziałaniu narkomanii z dn. 1 kwietnia 2011 roku przyniosła nowe rozwiązanie prawne, które daje specjalistom terapii uzależnień z certyfikatem wydanym przez Krajowe Biuro ds. Przeciwdziałania Narkomanii możliwość współpracy z organami wymiaru sprawiedliwości w zakresie opiniowania na temat używania nielegalnych substancji psychoaktywnych przez osoby podejrzane lub oskarżone. Jeśli prokurator lub sąd ma uzasadnione podejrzenie, że oskarżony może być uzależniony lub używa narkotyków szkodliwie jest zobowiązany zlecić specjaliście zebranie informacji na temat używania przez oskarżonego narkotyków. Na podstawie przygotowanych przez specjalistów ocen dotyczących charakteru używania substancji przez oskarżonego sąd lub prokuratura mogą podjąć decyzję o umorzeniu kary, bądź jej zawieszeniu na czas leczenia lub udziału w programie profilaktycznym.,

국립부곡병원 대표홈페이지 내 중독바로알기 웹서비스를 통하여 수집되는 중독진단 통계 데이터 현황(분류,진단명,년도,건수,주체,남성,여성,연령,(검사결과),지역)

The National Directory of Drug and Alcohol Abuse Treatment Programs 1994 lists federal, state, local, and private facilities that provide substance abuse treatment services. The directory includes treatment facilities that are licensed, certified, or otherwise approved for inclusion in the directory by their state substance abuse agencies and that responded to the 1993 National Survey of Substance Abuse Treatment Services (N-SSATS). The information about each facility that appears in this directory was provided by that facility in response to the 1993 N-SSATS. The Substance Abuse and Mental Health Services Administration (SAMHSA) conducts the N-SSATS annually.

Unduplicated Count of Clients by Primary Drug of Use Divided by Program Type